trending Market Intelligence /marketintelligence/en/news-insights/trending/LMHRTE8XFUjEcz25eg6yxg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bicycle Therapeutics secures £40M in financing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bicycle Therapeutics secures £40M in financing

Bicycle Therapeutics secured £40 million in a series B financing led by Vertex Ventures HC.

Other participants include new investors Cambridge Innovation Capital and Longwood Fund, as well as existing investors Novartis Venture Fund, SROne, SVLS and Atlas Venture.

The company said it will use proceeds to further develop its lead molecule BT1718, which targets malignant tumors.

Additionally, the financing will help advance Bicycle Therapeutics' preclinical programs, which include toxin drug conjugates and immune modulators.